Franco Perrone

1.7k total citations
71 papers, 1.2k citations indexed

About

Franco Perrone is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Franco Perrone has authored 71 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 11 papers in Epidemiology. Recurrent topics in Franco Perrone's work include Lung Cancer Research Studies (9 papers), Ovarian cancer diagnosis and treatment (9 papers) and Lung Cancer Treatments and Mutations (7 papers). Franco Perrone is often cited by papers focused on Lung Cancer Research Studies (9 papers), Ovarian cancer diagnosis and treatment (9 papers) and Lung Cancer Treatments and Mutations (7 papers). Franco Perrone collaborates with scholars based in Italy, Spain and United States. Franco Perrone's co-authors include Ciro Gallo, Maria Grazia Fabrini, Sabino De Placido, C. Rizzo, L. Cionini, G. Zavattini, G. Ruoso, F. Della Valle, Caterina Pagliarulo and Giuseppe Petrella and has published in prestigious journals such as Physical Review Letters, Journal of Clinical Oncology and Physics Letters B.

In The Last Decade

Franco Perrone

70 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Franco Perrone Italy 20 483 291 231 180 134 71 1.2k
M. Trovò Italy 21 450 0.9× 783 2.7× 137 0.6× 224 1.2× 127 0.9× 130 1.9k
F. Recchia Italy 19 549 1.1× 208 0.7× 52 0.2× 138 0.8× 79 0.6× 118 1.3k
Mathias Wagner Germany 25 456 0.9× 124 0.4× 578 2.5× 144 0.8× 61 0.5× 97 2.1k
Jingsheng Yan United States 26 431 0.9× 635 2.2× 78 0.3× 282 1.6× 90 0.7× 71 1.9k
John J. Feldmeier United States 34 264 0.5× 468 1.6× 79 0.3× 156 0.9× 102 0.8× 88 3.3k
Matthew S. Block United States 27 992 2.1× 224 0.8× 212 0.9× 171 0.9× 187 1.4× 142 2.3k
J. E. Dyson United Kingdom 26 461 1.0× 86 0.3× 145 0.6× 299 1.7× 78 0.6× 156 2.7k
M. Cinausero Italy 16 342 0.7× 396 1.4× 49 0.2× 129 0.7× 37 0.3× 66 898
Nobuaki Ochi Japan 21 820 1.7× 585 2.0× 103 0.4× 106 0.6× 142 1.1× 127 1.4k
W. Zeller Germany 22 375 0.8× 99 0.3× 164 0.7× 46 0.3× 52 0.4× 92 1.5k

Countries citing papers authored by Franco Perrone

Since Specialization
Citations

This map shows the geographic impact of Franco Perrone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franco Perrone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franco Perrone more than expected).

Fields of papers citing papers by Franco Perrone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franco Perrone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franco Perrone. The network helps show where Franco Perrone may publish in the future.

Co-authorship network of co-authors of Franco Perrone

This figure shows the co-authorship network connecting the top 25 collaborators of Franco Perrone. A scholar is included among the top collaborators of Franco Perrone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franco Perrone. Franco Perrone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goss, Geraldine, Gail Darling, Virginie Westeel, et al.. (2024). LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC). Annals of Oncology. 35. S1238–S1238. 17 indexed citations
2.
Perrone, Franco, et al.. (2023). Topical ivermectin ointment treatment of Demodex blepharitis: a 6-year retrospective study. Graefe s Archive for Clinical and Experimental Ophthalmology. 262(4). 1281–1288. 6 indexed citations
3.
Perrone, Franco, Concetta Laliscia, Claudio Traino, et al.. (2023). An empirical approach to the definition of the target margins in eye radiosurgery. Journal of Applied Clinical Medical Physics. 24(8). e13982–e13982. 1 indexed citations
4.
Laliscia, Concetta, et al.. (2021). Two different sizes of Valencia applicators in non-melanoma skin cancer treatment with iridium-192 high-dose-rate brachytherapy. Journal of Contemporary Brachytherapy. 13(6). 615–619. 2 indexed citations
5.
Laliscia, Concetta, et al.. (2021). High-dose-rate brachytherapy for non-melanoma skin cancer using tailored custom moulds – a single-centre experience. Współczesna Onkologia. 25(1). 12–16. 3 indexed citations
6.
Feo, Gianfranco De, Gerardo Botti, Arturo Capasso, et al.. (2020). Clinical trials and drug cost savings for Italian health service. BMC Health Services Research. 20(1). 1089–1089. 10 indexed citations
7.
Kulkarni, S., Scott A. Laurie, Glenwood Goss, et al.. (2018). P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC. Journal of Thoracic Oncology. 13(10). S480–S481. 3 indexed citations
8.
Laliscia, Concetta, D. Delishaj, Maria Grazia Fabrini, et al.. (2016). Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit?. Journal of Contemporary Brachytherapy. 6(6). 512–517. 23 indexed citations
9.
Delishaj, D., Concetta Laliscia, Bruno Manfredi, et al.. (2015). Non-melanoma skin cancer treated with high-dose-rate brachytherapy and Valencia applicator in elderly patients: a retrospective case series. Journal of Contemporary Brachytherapy. 6(6). 437–444. 40 indexed citations
10.
Cecere, Sabrina Chiara, Gennaro Daniele, Domenica Lorusso, et al.. (2015). Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial. Annals of Oncology. 26. vi33–vi33. 1 indexed citations
11.
Santoni, Matteo, Silvia Scoccianti, Ivan Lolli, et al.. (2013). Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. Journal of Neuro-Oncology. 113(3). 397–401. 14 indexed citations
12.
Facchini, Gaetano, Michele Caraglia, Alessandro Morabito, et al.. (2010). Metronomic administration of Zoledronic Acid and Taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial. Cancer Biology & Therapy. 10(6). 543–548. 41 indexed citations
13.
Fabrini, Maria Grazia, et al.. (2009). Perioperative High-Dose-Rate Brachytherapy in the Treatment of Recurrent Malignant Gliomas. Strahlentherapie und Onkologie. 185(8). 524–529. 20 indexed citations
14.
Fabrini, Maria Grazia, Franco Perrone, Stefano Santi, et al.. (2009). A single-institutional brachytherapy experience in the management of esophageal cancer. Brachytherapy. 9(2). 185–191. 8 indexed citations
15.
Fabrini, Maria Grazia, et al.. (2008). High-dose-rate brachytherapy in a large squamous cell carcinoma of the hand. Brachytherapy. 7(3). 270–275. 18 indexed citations
16.
Piermattei, A., et al.. (2003). Experimental and Monte Carlo Endovascular Dosimetry of a 192Ir Source. Physica Medica. 1000–1008. 1 indexed citations
17.
Placido, Sabino De, Michelino De Laurentiis, Chiara Carlomagno, et al.. (2003). Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.. PubMed. 9(3). 1039–46. 101 indexed citations
18.
Ménard, Sylvie, Patrizia Casalini, Gorana Tomasic, et al.. (1999). Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Research and Treatment. 55(2). 167–175. 44 indexed citations
19.
Gridelli, Cesare, Franco Perrone, Ciro Gallo, et al.. (1997). Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. European Journal of Cancer. 33(3). 392–397. 77 indexed citations
20.
Placido, Sabino De, Ciro Gallo, Franco Perrone, et al.. (1990). Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study. British Journal of Cancer. 62(4). 643–646. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Trovò Breakdown of academic impact, for papers by F. Recchia Breakdown of academic impact, for papers by Mathias Wagner Breakdown of academic impact, for papers by Jingsheng Yan Breakdown of academic impact, for papers by John J. Feldmeier Breakdown of academic impact, for papers by Matthew S. Block Breakdown of academic impact, for papers by J. E. Dyson Breakdown of academic impact, for papers by M. Cinausero Breakdown of academic impact, for papers by Nobuaki Ochi Breakdown of academic impact, for papers by W. Zeller
Rankless by CCL
2026